As mentioned before, Europe is losing leadership and competitiveness in NRF2-related pharmacology since products initially developed in Europe are being exploited in third countries. In this context, this WG will design the strategy to retain innovation and facilitate the transfer of knowledge to European industry by building bridges between academia and industry, and provide training and advice in knowledge/technology transfer and entrepreneurship to the next-generation researchers.